Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab

被引：4
|
作者：
Hertler, Caroline [1 ,2 ,3 ]
Seystahl, Katharina [1 ,2 ]
Le Rhun, Emilie [1 ,2 ,4 ]
Wirsching, Hans-Georg [1 ,2 ]
Roth, Patrick [1 ,2 ]
Weller, Michael [1 ,2 ]
Gramatzki, Dorothee [1 ,2 ]
机构：
[1] Univ Hosp, Clin Neurosci Ctr, Dept Neurol, Frauenklin str 26, CH-8091 Zurich, Switzerland
[2] Univ Zurich, Frauenklin str 26, CH-8091 Zurich, Switzerland
[3] Univ Hosp Zurich, Competence Ctr Palliat Care, Zurich, Switzerland
[4] Univ Hosp, Clin Neurosci Ctr, Dept Neurosurg, Zurich, Switzerland
来源：
NEURO-ONCOLOGY | 2022年 / 24卷 / 11期
关键词：
D O I：
10.1093/neuonc/noac172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2001 / 2004
页数：4
相关论文
共 50 条
  • [21] Bevacizumab in recurrent glioblastoma
    Martinez, Nina L.
    Glass, Jon
    Shi, Wenyin
    [J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S162 - S163
  • [22] CORRELATION OF MRI IMAGING CHARACTERISTICS WITH PATTERNS OF PROGRESSION IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB
    Qiao, Xin J.
    He, Ren
    Brown, Matthew
    Goldin, Jonathan
    Cloughesy, Timothy
    Pope, Whitney B.
    [J]. NEURO-ONCOLOGY, 2011, 13 : 144 - 144
  • [23] Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab
    R. A. Manneh Kopp
    J. M. Sepúlveda-Sánchez
    Y. Ruano
    O. Toldos
    A. Pérez Núñez
    D. Cantero
    A. Hilario
    A. Ramos
    G. de Velasco
    P. Sánchez-Gómez
    A. Hernández-Laín
    [J]. Clinical and Translational Oncology, 2019, 21 : 1413 - 1423
  • [24] EFFICACY AND TOLERABILITY OF BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
    Francini, E.
    Mazzaroppi, S.
    Salvati, M.
    Caponnetto, S.
    Laera, L.
    Migali, C.
    Bianco, V.
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [25] SUSCEPTIBILITY WEIGHTED IMAGING PREDICTS PROGRESSIVE DISEASE IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB
    Radbruch, A.
    Kramp, L.
    Wiestler, B.
    Heiland, S.
    Wick, W.
    Bendszus, M.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 10 - 10
  • [26] Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab
    Manneh Kopp, R. A.
    Sepulveda-Sanchez, J. M.
    Ruano, Y.
    Toldos, O.
    Perez Nunez, A.
    Cantero, D.
    Hilario, A.
    Ramos, A.
    de Velasco, G.
    Sanchez-Gomez, P.
    Hernandez-Lain, A.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (10): : 1413 - 1423
  • [27] Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
    Morisse, M. C.
    Etienne-Selloum, N.
    Bello-Roufai, D.
    Blonski, M.
    Taillandier, L.
    Lorgis, V.
    Noel, G.
    Ahle, G.
    Duran-Pena, A.
    Boone, M.
    Chauffert, B.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2019, 144 (02) : 419 - 426
  • [28] Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin
    Bennett, Iwan E.
    Field, Kathryn M.
    Hovens, Christopher M.
    Moffat, Bradford A.
    Rosenthal, Mark A.
    Drummond, Katharine
    Kaye, Andrew H.
    Morokoff, Andrew P.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2017, 131 (02) : 321 - 329
  • [29] Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment
    Sever, Ozlem Nuray
    Oktay, Kadir
    Guzel, Ebru
    Kaya, Vildan
    Guzel, Aslan
    Yildirim, Mustafa
    [J]. INDIAN JOURNAL OF CANCER, 2021, 58 (01) : 91 - 95
  • [30] Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme
    Schiff, David
    Purow, Benjamin
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (04): : 186 - 187
12345